Compare WNW & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WNW | LIXT |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | China | United States |
| Employees | N/A | 4 |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 25.3M |
| IPO Year | 2019 | N/A |
| Metric | WNW | LIXT |
|---|---|---|
| Price | $1.82 | $3.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.4K | ★ 30.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.64 |
| 52 Week High | $2.95 | $6.09 |
| Indicator | WNW | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 67.98 | 54.80 |
| Support Level | $1.63 | $2.97 |
| Resistance Level | $1.89 | $3.32 |
| Average True Range (ATR) | 0.10 | 0.27 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 88.24 | 85.71 |
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.